异位性皮肤炎临床试验市场- 按分子类型（大、小）、研究设计（介入性、观察性）、阶段（I、II、III、IV）、模式（外包、内部）、产业（製药和生物科技公司、 CRO），2024 - 2032 年全球预测

Atopic Dermatitis Clinical Trials Market - By Molecule Type (Large, Small), Study Design (Interventional, Observational), Phase (I, II, III, IV), Mode (Outsourced, In-house), Industry (Pharma & Biotech Companies, CRO's), Global Forecast 2024 - 2032

出版日期: 2024年03月14日 | 出版商:

Global Market Insights Inc. | 英文 165 Pages | 商品交期: 2-3个工作天内

价格

简介目录

在该领域临床试验和研发不断增加的推动下，2024 年至 2032 年间，全球异位性皮肤炎临床试验市场规模的复合年增长率将达到 11.4%。随着全球异位性皮肤炎盛行率的上升，製药公司、研究机构和医疗保健提供者正在加紧努力开发创新疗法和疗法。例如，2024年4月，处于临床阶段的生物製药公司Corvus Pharmaceuticals, Inc.宣布启动soquelitinib的1期临床试验。这项随机、安慰剂对照、双盲试验将评估索奎替尼对中度至重度异位性皮肤炎患者的疗效。

这些临床试验旨在评估新药、生物製剂和局部治疗对异位性皮肤炎患者的疗效、安全性和耐受性。此外，对该疾病潜在机制的了解的进步正在推动新治疗标靶的探索。因此，对参与者、研究设施和专业服务的需求不断增长，扩大了对异位性皮肤炎临床试验的需求并推动市场向前发展。

整个异位性皮肤炎临床试验产业根据研究设计、分子类型、阶段、模式、产业和地区进行分类。

小分子细分市场将在2024年至2032年经历严格的发展。凭藉小分子的多功能性和针对性方法，製药公司越来越多地将研究重点放在开发异位性皮肤炎的创新疗法上。与传统疗法相比，这些分子具有提高疗效和减少副作用的潜力，从而推动了临床试验的兴趣和投资。随着对有效和更安全治疗的需求不断增长，临床试验中小分子的探索仍然是推进异位性皮肤炎治疗领域的关键驱动力。

从2024 年到2032 年，观察性研究领域的异位性皮肤炎临床试验市场份额将出现显着的复合年增长率。关重要的作用。透过补充传统的临床试验，观察性研究为异位性皮肤炎治疗的长期有效性和安全性提供了有价值的见解。製药公司和研究人员越来越认识到观察资料的重要性，推动了进行此类研究的投资和兴趣，以满足患者和医疗保健提供者在治疗异位性皮肤炎方面不断变化的需求。

亚太地区异位性皮肤炎临床试验市场将在 2024 年至 2032 年呈现出值得称讚的复合年增长率。製药公司越来越多地在该地区进行临床试验，以解决影响疾病的独特遗传和环境因素。此外，监管机构正在简化审批流程，使其更有利于临床研究。这种迅速增长的需求凸显了该地区在推动异位性皮肤炎治疗和满足其人口医疗保健需求方面的重要性。例如，2023年12月，总部位于中国的生物製药公司诺诚健华宣布，ICP-332治疗异位性皮肤炎的II期临床试验取得了令人鼓舞的重要结果。

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 中东和非洲其他地区

第 11 章：公司简介

BIOCYTOGEN
Charles River Laboratories
Hooke Laboratories, LLC
Imavita
Novotech
Oncodesign services
QIMA LTD
Redoxis
REPROCELL Inc.
Syneos Health

简介目录

Product Code: 8508

Global Atopic Dermatitis Clinical Trials Market Size will witness 11.4% CAGR between 2024 and 2032, propelled by increasing clinical trials and R&D in the field. With the prevalence of atopic dermatitis on the rise globally, pharmaceutical companies, research institutions, and healthcare providers are intensifying their efforts to develop innovative treatments and therapies. For instance, in April 2024, Corvus Pharmaceuticals, Inc., a biopharmaceutical company in the clinical stage, announced the commencement of a Phase 1 clinical trial for soquelitinib. This trial, which was randomized, placebo-controlled, and double-blind, will assess the efficacy of soquelitinib in patients with moderate to severe atopic dermatitis.

These clinical trials aim to evaluate the efficacy, safety, and tolerability of new drugs, biologics, and topical treatments for atopic dermatitis patients. Moreover, advancements in understanding the underlying mechanisms of the disease are driving the exploration of novel therapeutic targets. As a result, there's a growing need for participants, research facilities, and specialized services, amplifying the demand for atopic dermatitis clinical trials and propelling the market forward.

The overall Atopic Dermatitis Clinical Trials Industry is classified based on the study design, molecule type, phase, mode, industry, and region.

The small molecules segment will undergo rigorous development from 2024 to 2032. With the versatility and targeted approach of small molecules, pharmaceutical companies are increasingly focusing their research efforts on developing innovative therapies for atopic dermatitis. These molecules offer the potential for improved efficacy and reduced side effects compared to traditional treatments, driving interest and investment in clinical trials. As the demand for effective and safer treatments continues to grow, the exploration of small molecules in clinical trials remains a key driver in advancing the field of atopic dermatitis therapeutics.

Atopic dermatitis clinical trials market share from the observational study segment will register a notable CAGR from 2024 to 2032. These studies play a crucial role in understanding disease progression, treatment outcomes, and patient experiences in real-world settings. By complementing traditional clinical trials, observational studies provide valuable insights into the long-term effectiveness and safety of atopic dermatitis treatments. Pharmaceutical companies and researchers are increasingly recognizing the importance of observational data, driving investment and interest in conducting such studies to address the evolving needs of patients and healthcare providers in managing atopic dermatitis.

Asia Pacific atopic dermatitis clinical trials market will showcase a commendable CAGR from 2024 to 2032. With a rising prevalence of atopic dermatitis in countries across Asia Pacific, there's a growing need for effective treatments. Pharmaceutical companies are increasingly conducting clinical trials in this region to address the unique genetic and environmental factors influencing the disease. Moreover, regulatory agencies are streamlining approval processes, making it more conducive for clinical research. This burgeoning demand underscores the region's importance in advancing atopic dermatitis therapeutics and catering to the healthcare needs of its population. For instance, in December 2023, InnoCare Pharma, a biopharmaceutical company headquartered in China, announced encouraging top-line findings from the Phase II clinical trial of ICP-332 for treating atopic dermatitis.

Chapter 1 Methodology & Scope

1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of atopic dermatitis
  - 3.2.1.2 Growing investments for research and development activities
  - 3.2.1.3 Increasing pipeline products for atopic dermatitis
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost associated with clinical trials
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
- 3.5.1 Supplier power
- 3.5.2 Buyer power
- 3.5.3 Threat of new entrants
- 3.5.4 Threat of substitutes
- 3.5.5 Industry rivalry
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Molecule Type, 2018 - 2032 ($ Mn)

5.1 Key trends
5.2 Large molecules
5.3 Small molecules

Chapter 6 Market Estimates and Forecast, By Study Design, 2018 - 2032 ($ Mn)

6.1 Key trends
6.2 Interventional study
6.3 Observational study
6.4 Expanded access study

Chapter 7 Market Estimates and Forecast, By Phase, 2018 - 2032 ($ Mn)

7.1 Key trends
7.2 Phase I
7.3 Phase II
7.4 Phase III
7.5 Phase IV

Chapter 8 Market Estimates and Forecast, By Mode, 2018 - 2032 ($ Mn)

8.1 Key trends
8.2 Outsourced
8.3 In-house

Chapter 9 Market Estimates and Forecast, By Industry, 2018 - 2032 ($ Mn)

9.1 Key trends
9.2 Contract research organizations
9.3 Pharmaceutical and biotechnology companies
9.4 Research and academic institutes

Chapter 10 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

10.1 Key trends
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Rest of Europe
10.4 Asia Pacific
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 Rest of Asia Pacific
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Rest of Latin America
10.6 Middle East and Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 Rest of Middle East and Africa